Peter J. Weiler appointed as new CFO of Edesa Biotech, starting May 1, 2025. Weiler brings extensive experience, with previous roles at Exzell Pharma and Biosyent Inc. Weiler holds an…
A pivotal leadership change occurs at Edesa Biotech as Peter J. Weiler is appointed CFO, bringing extensive experience in business development and pharmaceutical leadership. Weiler's background includes key roles at…
Peter J. Weiler joins Edesa Biotech as CFO on May 1, 2025, bringing extensive leadership in biotechnology and pharmaceuticals. Weiler's experience includes roles as President of Exzell Pharma and VP…
Peter J. Weiler appointed as Chief Financial Officer of Edesa Biotech, succeeding Stephen Lemieux. Weiler's leadership experience includes roles at Exzell Pharma, Biosyent Inc., and Cipher Pharmaceuticals. His background is…
Edesa Biotech appoints Peter J. Weiler as the new Chief Financial Officer, effective May 2025, succeeding Stephen Lemieux. Weiler brings extensive experience in corporate finance and strategic development from Exzell…
Edesa Biotech announces the appointment of Peter J. Weiler as the new Chief Financial Officer (CFO) starting May 2025, succeeding Stephen Lemieux. Peter J. Weiler brings extensive experience from roles…
Edesa Biotech appoints Peter J. Weiler as the new Chief Financial Officer, effective May 1, 2025, to lead financial strategy in developing therapies for immuno-inflammatory diseases. Stephen Lemieux transitions to…
Edesa Biotech has appointed Peter J. Weiler as its new Chief Financial Officer, effective May 1, 2025. Weiler brings extensive experience from leadership roles at Exzell Pharma, Biosyent Inc., and…
Dave Williamson leads innovations at Abzena, focusing on bioconjugates and ADCs to transform patient care globally. His diverse experiences, from the U.S. Army to pharmaceutical technology, fuel his passion for…